A COMPARATIVE EVALUATION OF A DISINTEGRIN AND METALLOPROTEINASE (ADAM )17 MARKER RESPONSE TO PERIODONTAL THERAPY IN DIABETES AND OBESE PATIENTS WITH AND WITHOUT PERIODONTITIS.
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Is there any difference in ADAM 17 levels in diabetic and
研究概览
简要总结
Periodontitis is a local inflammatory process mediating the destruction of periodontium
triggered by bacterial insult leading to systemic inflammatory mayhem in the host. It is a
prototype of low-grade local infection associated with a moderate systemic inflammatory
response. Patients suffering from severe forms of this disease seem to have perturbation of
their systemic homeostasis. Another way glycaemic levels and other factors like obesity are
also likely to affect the risk of periodontitis.
Epidemiological studies confirm that diabetes is a significant risk factor for periodontitis, and
the risk of periodontitis is greater if glycaemic control is poor; people with poorly controlled
diabetes, who are also most at risk for the other macrovascular and microvascular
complications are at an increased risk of periodontitis and alveolar bone loss
Obesity is a chronic metabolic disease that predisposes to a variety of comorbidities including
arterial hypertension, type 2 diabetes mellitus, atherosclerosis, and cardiovascular diseases.
Furthermore, obesity has been suggested to be a risk factor for periodontitis.
A Disintegrin And Metalloproteinase (ADAM) are proteins with characteristics of proteases that
are regularly found in the membrane of various cell types. It has been reported to cleave tumor
growth factor from the membrane. These ADAMs are implicated in a large number of diseases,
including diabetes, obesity, etc . Patients with periodontitis may have elevated circulating levels
of specific inflammatory markers that can be correlated to the severity of other systemic
diseases. These biomarkers of host response can be found in gingival crevicular fluid saliva and
serum samples can potentially be used as diagnostic markers. Would like to correlate how
ADAM17 will be interlinked with these three conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- None
入排标准
- 年龄范围
- 35.00 Year(s) 至 55.00 Year(s)（—）
- 性别
- All
入选标准
- •Known diabetic patients(Test group) patients with BMI values greater than 30(test group) Individuals with moderate periodontitis( according to 2017 classification) Patients who have not received periodontal therapy within preceeding 3months.
- •Patients should have atleast 15 teeth.
排除标准
- •Presence of any other systemic diseases,genetic diseases,and diseases which effect periodontitium Smokers,tobacco chewers and alcholics.
- •Patients with present and past history of antibiotics and anti inflammatory drugs in last 3 months.
- •Patients taking high dose of steroid therapy,radiation therapy or immunosuppressive therapy and any other medication for systemic diseases.Pregnant and lactating women.
- •patients undergoing treatment for obesity.
- •Mentally challenged and un cooperative patients.
- •Patients not complaint to oral hygiene instuctions and recall maintenance.
结局指标
主要结局
Is there any difference in ADAM 17 levels in diabetic and
时间窗: BASE LINE AND 3 MONTHS
obese patients
时间窗: BASE LINE AND 3 MONTHS
Is there any variation in the ADAM 17 levels before and after
时间窗: BASE LINE AND 3 MONTHS
periodontal therapy
时间窗: BASE LINE AND 3 MONTHS
次要结局
- Is there any variation in the clinical parameters after(periodontal therapy)
研究者
JAMMULA SURYA PRASANNA
Panineeya Mahavidyalaya Institute of Dental Sciences and Researchcentre